1 Chan HCH, Ng SC. Emerging biologics in in- flammatory bowel disease. J Gastroenterol. 2017 Feb;52(2):141–50.
2 Kaplan GG, Ng SC. Understanding and pre- venting the global increase of inflammatory bowel disease. Gastroenterology. 2017 Feb; 152(2):313–21.e2.
3 The Human Microbiome Project Consor- tium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13;486(7402):207–14.
4 The Human Microbiome Project Consortium. A framework for human microbiome research. Nature. 2012 Jun 13;486(7402):215–21.
5 Tisza MJ, Buck CB. A catalog of tens of thou- sands of viruses from human metagenomes reveals hidden associations with chronic dis- eases. Proc Natl Acad Sci U S A. 2021 Jun 8; 118(23):e2023202118.
6 Becker C, Neurath MF, Wirtz S. The intestinal microbiota in inflammatory Bowel disease. ILAR J. 2015;56(2):192–204.
7 Sartor RB, Wu GD. Roles for intestinal bacte- ria, viruses, and fungi in pathogenesis of in- flammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017 Feb; 152(2):327–39.e4.
8 Imai T, Inoue R, Kawada Y, Morita Y, Inatomi O, Nishida A, et al. Characterization of fungal dysbiosis in Japanese patients with inflamma- tory bowel disease. J Gastroenterol. 2019 Feb; 54(2):149–59.
9 Norman JM, Handley SA, Virgin HW. King- dom-agnostic metagenomics and the impor- tance of complete characterization of enteric microbial communities. Gastroenterology. 2014 May;146(6):1459–69.
10 Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017 Jun;66(6):1039– 48.
11 Zuo T, Lu XJ, Zhang Y, Cheung CP, Lam S, Zhang F, et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019 Jul;68(7):1169– 79.
12 Sartor RB. Microbial influences in inflamma- tory bowel diseases. Gastroenterology. 2008 Feb;134(2):577–94.
13 Tavakoli P, Vollmer-Conna U, Hadzi-Pav- lovic D, Grimm MC. A review of inflamma- tory bowel disease: a model of microbial, im- mune and neuropsychological integration. Public Health Rev. 2021;42:1603990.
14 Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010 Jan;18(1):190–5.
15 Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):577–89.
16 Marchesi JR, Adams DH, Fava F, Hermes GDA, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016 Feb;65(2):330–9.
17 McNeil NI. The contribution of the large in- testine to energy supplies in man. Am J Clin Nutr. 1984 Feb;39(2):338–42.
18 Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol. 2011 Nov; 45 Suppl:S120–7.
19 Simpson HL, Campbell BJ. Review article: di- etary fibre-microbiota interactions. Aliment Pharmacol Ther. 2015 Jul;42(2):158–79.
20 Duncan SH, Louis P, Thomson JM, Flint HJ. The role of pH in determining the species composition of the human colonic microbio- ta. Environ Microbiol. 2009 Aug;11(8):2112– 22.
21 Litvak Y, Byndloss MX, Tsolis RM, Baumler AJ. Dysbiotic proteobacteria expansion: a mi- crobial signature of epithelial dysfunction. Curr Opin Microbiol. 2017 Oct;39:1–6.
22 Litvak Y, Byndloss MX, Baumler AJ. Colono- cyte metabolism shapes the gut microbiota. Science. 2018 Nov;362(6418):eaat9076.
23 Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabo- lism. Front Cell Infect Microbiol. 2018;8:13.
24 Wlodarska M, Luo C, Kolde R, d’Hennezel E, Annand JW, Heim CE, et al. Indoleacrylic acid produced by commensal peptostrepto- coccus species suppresses inflammation. Cell Host Microbe. 2017 Jul 12;22(1):25–37.e6.
25 Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598–605.
26 Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):111–28.
27 Sinha SR, Haileselassie Y, Nguyen LP, Tropini C, Wang M, Becker LS, et al. Dysbiosis-in- duced secondary bile acid deficiency pro- motes intestinal inflammation. Cell Host Mi- crobe. 2020 Apr 8;27(4):659–70.e5.
28 Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005 Sep;29(4):625–51.
29 Kamada N, Nunez G. Regulation of the im- mune system by the resident intestinal bacte- ria. Gastroenterology. 2014 May; 146(6):1477–88.
30 Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clos- tridium species. Science. 2011 Jan 21; 331(6015):337–41.
31 Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal mi- crobe-derived butyrate induces the differen- tiation of colonic regulatory T cells. Nature. 2013 Dec 19;504(7480):446–50.
32 Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The mi- crobial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Sci- ence. 2013 Aug 2;341(6145):569–73.
33 Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gas- troenterol Hepatol. 2013 Apr;28(4):613–9.
34 Waite JC, Skokos D. Th17 response and in- flammatory autoimmune diseases. Int J In- flam. 2012;2012:1–10.
35 Atarashi K, Tanoue T, Ando M, Kamada N, Nagano Y, Narushima S, et al. Th17 cell in- duction by adhesion of microbes to intestinal epithelial cells. Cell. 2015 Oct 8;163(2):367–80.
36 Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients. 2011 Oct;3(10): 858–76.
37 Andoh A, Fujiyama Y, Hata K, Araki Y, Taka- ya H, Shimada M, et al. Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced comple- ment C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol. 2001;118(1):23–9.
38 Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005 Dec 19;363:15–23.
39 Halsall J, Gupta V, O’Neill LP, Turner BM, Nightingale KP. Genes are often sheltered from the global histone hyperacetylation in- duced by HDAC inhibitors. PLoS One. 2012; 7(3):e33453.
40 Frank DN, Robertson CE, Hamm CM, Kpa- deh Z, Zhang T, Chen H, et al. Disease pheno- type and genotype are associated with shifts in intestinal-associated microbiota in inflam- matory bowel diseases. Inflamm Bowel Dis. 2011 Jan;17(1):179–84.
41 Nagalingam NA, Lynch SV. Role of the mi- crobiota in inflammatory bowel diseases. In- flamm Bowel Dis. 2012 May;18(5):968–84.
42 Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, et al. Reduced abun- dance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016;93(1):59–65.
43 Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, et al. Analysis of endoscop- ic brush samples identified mucosa-associat- ed dysbiosis in inflammatory bowel disease. J Gastroenterol. 2017 Aug;53(1):95–106.
44 Willing BP, Dicksved J, Halfvarson J, Anders- son AF, Lucio M, Zheng Z, et al. A pyrose- quencing study in twins shows that gastrointes- tinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010 Dec;139(6):1844–54.e1.
45 Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, et al. Analysis of endoscop- ic brush samples identified mucosa-associat- ed dysbiosis in inflammatory bowel disease. J Gastroenterol. 2018 Jan;53(1):95–106.
46 Sheehan D, Moran C, Shanahan F. The mi- crobiota in inflammatory bowel disease. J Gastroenterol. 2015 May;50(5):495–507.
47 Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019 May;569(7758):655–62.
48 Li J, Chen D, Yu B, He J, Zheng P, Mao X, et al. Fungi in gastrointestinal tracts of human and mice: from community to functions. Mi- crob Ecol. 2018 May;75(4):821–9.
49 Cui L, Morris A, Ghedin E. The human my- cobiome in health and disease. Genome Med. 2013;5(7):63.
50 Levitz SM. Innate recognition of fungal cell walls. PLoS Pathog. 2010 Apr 22; 6(4): e1000758.
51 Zuo T, Ng SC. The gut microbiota in the patho- genesis and therapeutics of inflammatory bow- el disease. Front Microbiol. 2018;9:2247.
52 Norman JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-spe- cific alterations in the enteric virome in in- flammatory bowel disease. Cell. 2015 Jan 29; 160(3):447–60.
53 Maronek M, Link R, Ambro L, Gardlik R. Phages and their role in gastrointestinal dis- ease: focus on inflammatory bowel disease. Cells. 2020 Apr 18;9(4):1013.
54 Ungaro F, Massimino L, D’Alessio S, Danese S. The gut virome in inflammatory bowel disease pathogenesis: from metagenomics to novel therapeutic approaches. United European Gas- troenterol J. 2019 Oct;7(8):999–1007.
55 Minot S, Bryson A, Chehoud C, Wu GD, Lew- is JD, Bushman FD, et al. Rapid evolution of the human gut virome. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12450–5.
56 Beller L, Matthijnssens J. What is (not) known about the dynamics of the human gut virome in health and disease. Curr Opin Virol. 2019 Aug;37:52–7.
57 Waller AS, Yamada T, Kristensen DM, Kul- tima JR, Sunagawa S, Koonin EV, et al. Clas- sification and quantification of bacteriophage taxa in human gut metagenomes. ISME J. 2014 Jul;8(7):1391–402.
58 Perez-Brocal V, Garcia-Lopez R, Nos P, Bel- tran B, Moret I, Moya A, et al. Metagenomic analysis of Crohn’s disease patients identi- fies changes in the virome and microbiome related to disease status and therapy, and de- tects potential interactions and biomarkers. Inflamm Bowel Dis. 2015 Nov;21(11):2515– 32.
論文の公開元へ
